SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Overgaard Ulrik) "

Sökning: WFRF:(Overgaard Ulrik)

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Nadine G., et al. (författare)
  • A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries : Different practices of assessment and management
  • 2022
  • Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 199:1, s. 117-121
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients undergoing treatment for acute lymphoblastic leukaemia (ALL) are at risk of coagulopathy, especially thromboembolism. We conducted a survey on practices in the assessment and management of coagulopathy during the new ALLTogether protocol in 29 (17 paediatric, 12 adult) Nordic and Baltic cancer centres. While 92% of adult centres used thromboprophylaxis with low-molecular-weight heparin, no paediatric centre did. Almost all providers performed baseline coagulation studies, but only 59% continued the assessment. Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.
  •  
2.
  •  
3.
  • Egnell, Christina, et al. (författare)
  • Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia
  • 2023
  • Ingår i: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 62:12, s. 1723-1731
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Data on outcome for patients in different body mass index (BMI) categories in young adults with acute lymphoblastic leukemia (ALL) are scarce. We explored survival and toxicities in different BMI categories in young adults with ALL.Material and methods: Patients aged 18-45 years, diagnosed with ALL between July 2008 and June 2022 in the Nordic countries, Estonia, or Lithuania, and treated according to the NOPHO ALL2008 protocol, were retrospectively enrolled and classified into different BMI categories. Endpoints were overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse as well as incidence rate ratio (IRR) of severe predefined toxic events, and treatment delays.Results: The group comprised 416 patients, of whom 234 (56%) were stratified to non-high-risk (non-HR) treatment. In the non-HR group, patients with severe obesity, BMI & GE;35 kg/m2 had worse EFS due to relapses but there was no effect on toxicity or treatment delays compared with the healthy-weight patients. There was no association between BMI category and OS, overall toxicity, or treatment delays in the patients with high-risk treatment.Conclusion: Severe obesity is associated with worse EFS in young adults treated according to the non-HR arms of the NOPHO ALL2008 protocol. Poorer outcome is explained with a higher risk of relapse, possibly due to under treatment, and not caused by excess therapy-related mortality.
  •  
4.
  • Ljung, Rolf, et al. (författare)
  • Konstitutionella anemier
  • 2012. - 1
  • Ingår i: Blodets sjukdomar : Lärobok i hematologi - Lärobok i hematologi. - 9789144069241 ; , s. 241-253
  • Bokkapitel (refereegranskat)
  •  
5.
  • Rank, Cecilie U., et al. (författare)
  • Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia : Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
  • 2020
  • Ingår i: Journal of Clinical Oncology. - Alexandria : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 38:2, s. 145-154
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored.PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse.CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse.
  •  
6.
  • Risum, Malene, et al. (författare)
  • Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis : A Pre and Post-Intervention Analysis
  • 2020
  • Ingår i: JOURNAL OF FUNGI. - : MDPI. - 2309-608X. ; 6:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Mucormycosis is a life threatening infection in patients with haematological disease. We introduced a Mucorales-PCR and an aggressive, multidisciplinary management approach for mucormycosis during 2016-2017 and evaluated patient outcomes in 13 patients diagnosed and treated in 2012-2019. Management principle: repeated surgical debridement until biopsies from the resection margins were clean as defined by negative Blankophor microscopy, Mucorales-PCR (both reported within 24 h), and cultures. Cultured isolates underwent EUCAST E.Def 9.3.1 susceptibility testing. Antifungal therapy (AFT) (mono/combination) combined with topical AFT (when possible) was given according to the minimal inhibitory concentration (MIC), severity of the infection, and for azoles, specifically, it was guided by therapeutic drug monitoring. The outcome was evaluated by case record review. All patients underwent surgery guided by diagnostic biopsies from tissue and resection margins (195 samples in total). Comparing 2012-2015 and 2016-2019, the median number of patients of surgical debridements was 3 and 2.5 and of diagnostic samples: microscopy/culture/PCR was 3/3/6 and 10.5/10/10.5, respectively. The sensitivity of microscopy (76%) and Mucorales-PCR (70%) were similar and microscopy was superior to that of culture (53%; p = 0.039). Initial systemic AFT was liposomal amphotericin B (n = 12) or posaconazole (n = 1) given as monotherapy (n = 4) or in combination with isavuconazole/posaconazole (n = 3/6) and terbinafine (n = 3). Nine patients received topical amphotericin B. All received isavuconazole or posaconazole consolidation therapy (n = 13). Mucormycosis related six month mortality was 3/5 in 2012-2015 and 0/7 patients in 2016-2019 (one patient was lost for follow-up). Implementation of combination therapy (systemic+topical AFT/combination systemic AFT) and aggressive surgical debridement guided by optimised diagnostic tests may improve the outcome of mucormycosis in haematologic patients.
  •  
7.
  • Severinsen, Kaare, et al. (författare)
  • Skeletal muscle fiber characteristics and oxidative capacity in hemiparetic stroke survivors
  • 2016
  • Ingår i: Muscle and Nerve. - : Wiley. - 0148-639X .- 1097-4598. ; 53:5, s. 748-754
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Skeletal muscle is changed after stroke, but conflicting data exist concerning muscle morphology and oxidative enzyme capacity. Methods: In 36 chronic stroke patients bilateral rectus femoris muscle biopsies were analyzed, and fiber type proportions and cross-sectional areas were determined by ATPase histochemistry. Enzymatic concentrations of citrate synthase (CS) and 3-Hydroxyacyl-coenzymeA-dehydrogenase (HAD) were determined using freeze-dried muscle tissue. Findings were correlated with clinical outcomes. Results: In the paretic muscles the mean fiber area was smaller (P=0.0004), and a lower proportion of type 1 fibers (P=0.0016) and a higher proportion of type 2X fibers (P=0.0002) were observed. The paretic muscle had lower CS (P=0.013) and HAD concentrations (P=0.037). Mean fiber area correlated with muscle strength (r=0.43; P=0.041), and CS concentration correlated with aerobic capacity (r=0.47; P=0.01). Conclusions: In stroke survivors there is a phenotypic shift toward more fatigable muscle fibers with reduced oxidative enzymatic capacity that relates to clinical outcomes. Muscle Nerve53: 748-754, 2016
  •  
8.
  • Toksvang, Linea Natalie, et al. (författare)
  • Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia : a NOPHO ALL2008 sub-study
  • 2021
  • Ingår i: Cancer Chemotherapy and Pharmacology. - : Springer. - 0344-5704 .- 1432-0843. ; 88:5, s. 911-917
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose Osteonecrosis is a burdensome treatment-related toxicity that is mostly diagnosed during or soon after 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy for acute lymphoblastic leukemia (ALL), possibly indicating a pathogenic role of these drugs. Methods We prospectively registered symptomatic osteonecrosis during treatment of 1234 patients aged 1.0-45.9 years treated according to the Nordic Society of Hematology and Oncology (NOPHO) ALL2008 protocol. MTX/6MP metabolites were measured as part of the NOPHO ALL2008 maintenance therapy study. Results After a median follow-up of 5.6 years [interquartile range (IQR) 3.6-7.5], 68 patients had been diagnosed with symptomatic osteonecrosis. The cumulative incidence was 2.7% [95% confidence interval (CI) 1.6-3.8%] for patients aged < 10 years, 14.9% (95% CI 9.7-20.2%) for patients aged 10.0-17.9 years, and 14.4% (95% CI 8.0-20.8%) for patients aged >= 18 years. The median time from diagnosis of ALL to diagnosis of osteonecrosis in these age groups was 1.0 year (IQR 0.7-2.0), 2.0 years (IQR 1.1-2.4), and 2.2 years (IQR 1.8-2.8), respectively (p = 0.001). With 17,854 blood samples available for MTX and 6MP metabolite analysis, neither erythrocyte levels of 6-thioguanine (TG) nucleotides (p > 0.99), methylated 6MP metabolites (p = 0.37), MTX polyglutamates (p = 0.98) nor DNA-TG (p = 0.53) were significantly associated with the hazard of osteonecrosis in Cox models stratified by the three age groups and adjusted for sex. Conclusion Maintenance therapy intensity determined by 6MP and MTX metabolites was not associated with the risk of developing osteonecrosis in the NOPHO ALL2008 cohort.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
Typ av publikation
tidskriftsartikel (7)
konstnärligt arbete (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (8)
Författare/redaktör
Schmiegelow, Kjeld (4)
Griskevicius, Laimon ... (4)
Harila-Saari, Arja H ... (3)
Overgaard, Ulrik (3)
Abrahamsson, Jonas (2)
Albertsen, Birgitte ... (2)
visa fler...
Heyman, Mats (2)
Jonsson, Olafur Gisl ... (2)
Ranta, Susanna (2)
Joelsson, Joel (2)
Wartiovaara-Kautto, ... (2)
Hallböök, Helene (2)
Malmros, Johan (2)
Juliusson, Gunnar (1)
Jonsson, Olafur G. (1)
Karlsson, Mats O. (1)
Gylfe, Åsa, 1972- (1)
Ljung, Rolf (1)
Heyman, Mats M. (1)
Johannsdottir, Inga ... (1)
Niinimäki, Riitta (1)
Taskinen, Mervi (1)
Vaitkeviciene, Goda (1)
Vaitkeviciene, Goda ... (1)
Andersen, Henning (1)
Friberg, Lena E (1)
Ørtenblad, Niels (1)
Andersson, Nadine G. (1)
Rathe, Mathias (1)
Mølle, Ingolf (1)
Jarvis, Kirsten Brun ... (1)
Hoffmann, Marianne (1)
Huurre, Anu (1)
Lohi, Olli (1)
Långström, Satu (1)
Saulyte Trakymiene, ... (1)
Vepsäläinen, Kaisa (1)
Vogt, Hartmut, 1970- (1)
Andrés-Jensen, Liv (1)
Noren-Nyström, Ulrik ... (1)
Kampmann, Peter (1)
Tomaszewska-Toporska ... (1)
Gahrton, Gösta (1)
Wehner, Peder S (1)
Severinsen, Marianne ... (1)
Centanni, Maddalena (1)
Dam, Merete (1)
Centanni, Daniel (1)
Stensig Lynggaard, L ... (1)
Wik, Hilde Skuterud (1)
visa färre...
Lärosäte
Karolinska Institutet (5)
Uppsala universitet (4)
Umeå universitet (2)
Lunds universitet (2)
Linköpings universitet (1)
Mittuniversitetet (1)
Språk
Engelska (7)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (7)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy